EGFR R451C

CI-VAR-00003854Explore in graph →NP_001333827.1:p.Arg451CysNM_001346898.1:c.1351C>TClinVar 1018687 CIViC 454 rs377567759

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
EGFR R451C	Cetuximab + Futuximab/Modotuximab Mixture + PanitumumabSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID1081 In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetux… (full text at CIViC) PMID 26888827 · Sánchez-Martín et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
1018687	Uncertain significance	criteria provided, multiple submitters, no conflicts	2	EGFR-related lung cancer; Hereditary cancer-predisposing syndrome	germline	2	Jul 18, 2025	clinvar